Polio vaccine

Polio vaccine
USAID · Public domain · source
Name	Polio vaccine
Type	Vaccine
Target	Poliomyelitis
Inventor	Jonas Salk, Albert Sabin
Vaccine type	Inactivated vaccine, Live attenuated vaccine
First administered	1955
Provider	World Health Organization, Centers for Disease Control and Prevention, United Nations

Polio vaccine The polio vaccine is a preventive immunization developed to protect against poliomyelitis caused by poliovirus serotypes. It transformed public health during the mid-20th century through coordinated efforts by researchers, public institutions, and international campaigns. The development, deployment, and global eradication initiatives connected scientists, philanthropists, and agencies across multiple countries.

History

Early laboratory work by Karl Landsteiner and Erwin Popper identified poliovirus in the early 20th century, while clinical and epidemiological efforts by Jonas Salk, Albert Sabin, and teams at University of Pittsburgh and Ohio State University led to vaccine candidates. Landmark events include the 1955 announcement of trial results at venues attended by representatives from National Foundation for Infantile Paralysis and observers from U.S. Public Health Service. Subsequent field implementations intersected with programs from World Health Organization, the Bill & Melinda Gates Foundation, and national ministries such as Ministry of Health (India) and Ministry of Health, Labour and Welfare (Japan). International immunization days and initiatives, coordinated under Global Polio Eradication Initiative and supported by Rotary International, expanded coverage in regions including Sub-Saharan Africa, South Asia, and Latin America. Political and logistical milestones involved negotiations with governments like India, Pakistan, and Nigeria, and partnerships with manufacturers such as Eli Lilly and Company and GlaxoSmithKline.

Types and composition

Two principal formulations dominate: an inactivated injectable formulation developed by Jonas Salk and a live attenuated oral formulation developed by Albert Sabin. The inactivated vaccine is produced by inactivating poliovirus strains inactivated under protocols influenced by standards from Food and Drug Administration and quality bodies in European Medicines Agency. The live oral vaccine contains attenuated strains adapted through passages in cell culture laboratories reminiscent of historical work at Rockefeller Institute for Medical Research and later produced by companies including Sanofi and Bharat Biotech. Component profiles include viral antigens derived from poliovirus serotypes 1, 2, and 3, often combined with adjuvants or stabilizers as specified by standards from World Health Organization and pharmacopoeias like United States Pharmacopeia.

Mechanism of action

The inactivated injectable vaccine elicits systemic humoral immunity through induction of neutralizing antibodies targeting capsid proteins identified in structural studies by teams at Cold Spring Harbor Laboratory and Max Planck Institute for Biophysical Chemistry. The live attenuated oral vaccine replicates in the gut mucosa, inducing mucosal IgA responses and community-level herd immunity, mechanisms investigated in studies by researchers at Johns Hopkins University and University of California, San Francisco. Cellular and molecular immunology insights derive from contributions by immunologists such as Max Theiler and institutions like Pasteur Institute; these efforts clarified interactions with innate immune pathways described in work associated with National Institutes of Health.

Efficacy and safety

Randomized trials announced in 1955 and subsequent post-marketing surveillance informed efficacy estimates published in journals affiliated with Royal Society-linked societies and institutions including Harvard Medical School. The inactivated vaccine shows high efficacy in preventing paralytic disease, while oral vaccine demonstrated effectiveness in mass campaigns across Egypt, Israel, and Brazil. Safety monitoring by World Health Organization and national regulators such as Medicines and Healthcare products Regulatory Agency identified rare adverse events, including vaccine-associated paralytic poliomyelitis linked to live vaccine use, prompting strategic shifts endorsed by advisory committees such as those convened by Advisory Committee on Immunization Practices. Periodic policy changes have been coordinated with stakeholders like UNICEF.

Immunization schedules and global programs

National schedules established by ministries such as Ministry of Health (United Kingdom) and Ministry of Health (Australia) integrate inactivated and oral formulations according to recommendations from World Health Organization and Centers for Disease Control and Prevention. Mass campaigns—National Immunization Days—have been run in partnership with Rotary International, Bill & Melinda Gates Foundation, and Gavi, the Vaccine Alliance targeting endemic areas including Afghanistan and Pakistan. Eradication strategies encompass surveillance supported by networks like the Global Polio Laboratory Network and leverage logistics from organizations such as Médecins Sans Frontières and International Federation of Red Cross and Red Crescent Societies.

Production and quality control

Manufacture occurs in facilities certified by agencies such as Food and Drug Administration and inspected under standards from World Health Organization. Quality control includes viral seed characterization historically performed in reference labs like Centers for Disease Control and Prevention and adherence to release assays described in pharmacopeias of European Pharmacopoeia and United States Pharmacopeia. Scaling initiatives involved industrial partners such as Serum Institute of India and biopharmaceutical companies like GlaxoSmithKline and Sanofi Pasteur, with supply chain management coordinated with distribution partners including UNICEF.

Controversies and challenges

Controversies have involved vaccine access debates engaging entities like World Health Organization and advocacy groups including Greenpeace in broader public health dialogues. Misinformation campaigns intersected with sociopolitical dynamics in regions influenced by events such as the Nigerian polity-related vaccine boycott and tensions involving Taliban-affected areas. Security challenges have endangered health workers, prompting responses coordinated with organizations including United Nations Security Council resolutions and NGOs like Red Cross. Technical challenges include vaccine-derived poliovirus outbreaks monitored by Global Polio Eradication Initiative and policy shifts such as phased withdrawal coordinated by Strategic Advisory Group of Experts on Immunization.

Category:Vaccines